As­traZeneca sweeps out a PhI­II asth­ma flop, a PD-1 drug and some oth­er re­jects as Q4 tal­ly dis­ap­points

As­traZeneca dis­posed a late-stage asth­ma flop and a few oth­er ear­ly-stage as­sets this morn­ing as it faced a grow­ing cho­rus of crit­i­cism over its per­sis­tent­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER